Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis.

Trial Profile

Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Azelastine/fluticasone-propionate (Primary) ; Fluticasone propionate
  • Indications Allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Meda Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2017 Efficacy results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 20 Feb 2015 Dymista [Azelastine/fluticasone propionate] was approved by US FDA for children aged 6-11 years based on the data from this and another phase III trial, as per MEDA media release.
    • 25 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top